In vitro studies suggest that effective tumor suppression by p53 requires multiple domains to execute transcriptiondependent and transcription-independent functions. We generated a mutant p53 allele in mice, p53 W25QL26S (p53 QS ), containing an inactive transactivation domain to evaluate the importance of transactivation for p53-mediated tumor suppression. Recently, we discovered that the allele also contains a valine substitution for alanine at codon 135, which borders the DNA-binding domain. We found that p53
In vitro studies suggest that effective tumor suppression by p53 requires multiple domains to execute transcriptiondependent and transcription-independent functions. We generated a mutant p53 allele in mice, p53 W25QL26S (p53 QS ), containing an inactive transactivation domain to evaluate the importance of transactivation for p53-mediated tumor suppression. Recently, we discovered that the allele also contains a valine substitution for alanine at codon 135, which borders the DNA-binding domain. We found that p53
QSval135 bound to chromatin albeit less well than p53 QSala135 , but both were equally deficient in transcriptional regulation, apoptosis induction in mouse embryo fibroblasts (MEFs), and suppression of tumor formation by E1A, Ha-Ras transformed MEFs. p53
QSval135 mice and p53-null mice exhibited identical tumor development kinetics and spectra in spontaneous and oncogene-initiated tumorigenicity assays, when tested in a homo-and heterozygous configuration. The p53
QSval135 allele did not have dominant negative functions and behaved as a null allele. Taken together, these data indicate that effective tumor suppression requires the transcriptional regulation function of p53, and they suggest that transactivation independent functions of p53 are unlikely to contribute significantly to tumor suppression in vivo.
Introduction p53 signaling is functionally disabled in the majority of human cancers encompassing most tumor types (Nigro et al., 1989; Hollstein et al., 1991; Levine et al., 1991) , and p53 gene disruption in mice leads to spontaneous tumor development and early death (Donehower et al., 1992; Jacks et al., 1994) . These data firmly establish p53 as a tumor suppressor gene in vertebrates, but the mechanisms accounting for effective tumor suppression in vivo are still debated.
p53 is an unstable transcription factor, the abundance and activity of which are regulated predominantly by the E3 ubiquitin ligase MDM2 (Michael and Oren, 2003) . The MDM2 gene is activated by p53, creating a negative feedback loop to prevent precocious activation (see Wahl and Carr, 2001 for references). p53 is activated by diverse stresses, including DNA damage, hypoxia, aberrant oncogene expression, and ribonucleotide pool depletion, leading to cell cycle arrest, DNA repair, apoptosis, or cellular senescence (Wahl and Carr, 2001; Vousden and Lu, 2002) . Post-translational modifications such as phosphorylation of N-and C-terminal serines and acetylation of the C-terminus (Appella and Anderson, 2001; Brooks and Gu, 2003) , and MDM2 modifications that lead to accelerated MDM2 degradation, lead to p53 stabilization, and target gene activation (Stommel and Wahl, 2004) .
p53-mediated transcriptional regulation and binding to target gene promoters correlate well with tumor suppression (Vogelstein and Kinzler, 1992; Prives, 1994) . Furthermore, the biological functions of p53 most likely responsible for tumor suppression, cell cycle arrest, apoptosis, and DNA repair can be accounted for by its ability to activate or repress many target genes eliciting these effects (for recent reviews, see Vousden, 2000; Vousden and Lu, 2002; Wahl and Carr, 2001 ). On the other hand, some studies in cultured cells suggest that p53 can induce apoptosis independent of transcription (Caelles et al., 1994; Haupt et al., 1995; Haupt et al., 1997) through its interaction with mitochondria, direct activation of proapoptotic BH3-only proteins, or inactivation of antiapoptotic proteins such as Bcl-2 (Marchenko et al., 2000; Mihara et al., 2003; Chipuk et al., 2004) . p53 may also limit genetic instability by directly contributing to repair of double-strand breaks and base damage (Mummenbrauer et al., 1996; Sturzbecher et al., 1996; Offer et al., 2001; Zhou et al., 2001; Rubbi and Milner, 2003) .
Genetically engineered mice enable analysis of whether transcription-dependent and transcription-independent p53 functions and distinct p53 functional domains are required to suppress tumor formation in different tissues, or in response to various oncogenic stimuli. For example, the cell cycle arrest function of p53 is implicated in tumor suppression by the p53 R172P mutant, which is defective in apoptosis induction but competent to induce p21 (Liu et al., 2004) . Mice expressing p53
R172P escape the early onset of lymphomas observed in p53-null mice, but tumors eventually arise that are largely diploid (Liu et al., 2004) . By contrast, p53-dependent apoptosis is critical to limit the development of choroid plexus tumors initiated by inactivation of the pRb pathway (Symonds et al., 1994; Lu et al., 2001) , or the induction of lymphomas initiated by c-Myc expression (Schmitt et al., 2002) .
The contribution of the N-terminal p53 transactivation domain to tumor suppression also remains to be defined. Previous work showed that mutation of two adjacent highly conserved residues in the p53 N-terminus (L22QW23S in human; L25QW26S in mouse) severely disables transactivation measured in vitro (Lin et al., 1994) and in mice (Chao et al., 2000; Jimenez et al., 2000) . Consequently, p53
L25QW26S (referred to below as p53 QS ) does not induce cell cycle arrest or apoptosis in response to DNA damage and other stresses in thymocytes or mouse embryo fibroblasts (MEFs) analysed in vitro (Chao et al., 2000; Jimenez et al., 2000) . However, other studies implicate additional residues in the N-terminus as well as in the C-terminal regulatory domain in p53-mediated transcriptional control (Candau et al., 1997; Venot et al., 1999; Zhu et al., 1999; Barlev et al., 2001) . In addition, a recent study showed that MEFs derived from the p53 QS mice generated in this lab underwent apoptosis in vitro via a transcription-independent cytoplasmic mechanism (Chipuk et al., 2004) . This is consistent with other work indicating transcription-independent mechanisms for p53-induced apoptosis involving p53-mitochondrial interactions (Mihara et al., 2003; Chipuk et al., 2004; Leu et al., 2004) .
The initial description of the p53 QS mice used mainly in vitro methods to study the biological effects of this mutation (Jimenez et al., 2000) . The current report analyses the ability of p53 QS to suppress tumor formation in several mouse models. We performed extensive tumor analyses to compare the p53 QS and p53-null mice over a period of up to 2 years. Recently, we discovered that the parental targeting construct contains a mutation that generates valine substitution for alanine at codon 135 in p53 QS , which can engender conformational temperature sensitivity that can compromise p53 function. However, due to the elevated abundance of the stable p53
QSval protein, the amount of p53 QSval in the wildtype conformation in vivo exceeded that of wild-type p53 in normal cells. p53
QSval bound to chromatin in vivo, but generally less well than wild-type p53 or p53 QSala . On the other hand, the p53
QSala and p53 QSval were equally deficient in target gene activation, apoptosis induction, and suppression of tumorigenicity in a nude mouse xenograft model. Importantly, p53
QSval was equivalent to a p53-null allele with regard to suppression of spontaneous tumor development (tumor incidence, latency, and spectrum) and oncogene-induced tumor progression in a choroid plexus tumorigenesis model.
Results

L25QW26S (p53
QS
) mutation disables p53 function in mice
The p53 QS mutation was generated with a genomic targeting construct used previously to generate a p53-null allele (Donehower et al., 1992; Jimenez et al., 2000) . A recent analysis of cDNA derived from p53 QS MEFs revealed that alanine 135 was replaced by valine, which we showed to be present in the original targeting clone, and in the genomic p53 QS allele. Conflicting reports have appeared on the functional consequences of val135. While this substitution can elicit temperature sensitivity (Milner and Medcalf, 1990; Martinez et al., 1991) and a mutant conformation that exhibits oncogenic activity in in vitro transformation assays (Michalovitz et al., 1990; Martinez et al., 1991) , transgenic mouse strains exhibit different phenotypes ranging from modest tumor predisposition (Lavigueur et al., 1989) to premature senescence (Tyner et al., 2002) .
The val135 mutation elicits a temperature sensitivity that can affect subcellular location and conformation (Milner and Medcalf, 1990) (Martinez et al., 1991). p53 QSval is predominantly nuclear at both the permissive and nonpermissive temperatures (see Supplementary information, Figure S1A ). We examined the conformation of p53 in thymus of p53 QSval mice using discriminating antibodies. p53
QSval samples exhibited both wild-type and mutant conformations, while the wild-type sample contained the expected predominance of wild-type conformer ( Figure 1a) . However, the greater stability and abundance of the p53
QSval protein (Chao et al., 2000; Jimenez et al., 2000) yielded more wild-type conformer in p53
QSval thymic tissue than in g-irradiated p53
þ / þ tissue ( Figure 1a ). We next analysed the chromatin-binding activity of p53
QSval protein in the thymus. Since neither p53
QSval levels nor its binding to DNA changes upon stress (see below and Supplementary information, Figure S2 ), we examined p53 QSval chromatin binding in unstressed p53
QSval/QSval animals compared to chromatin binding of wild-type p53 in thymus of untreated or irradiated p53 þ / þ mice. As expected, irradiation increased the abundance and chromatin binding of wild-type p53 to its response elements in the p21, Mdm2, Noxa, and Puma genes ( Figure 1b) . Although p53
QSval protein is more abundant than wild-type p53 in unstressed cells, it bound at similar or somewhat lower levels than wild-type p53 did to these promoters in vivo (Figure 1b) .
We compared the chromatin-binding activity and various biological functions of p53
QSval and p53 QSala (i.e. (Figure 1c) . By contrast, p53
QSala bound better to the tested promoters, at similar levels as wild-type p53 did in adriamycin-treated cells (Figure 1c) . Importantly, neither p53
QSala nor p53 QSval induced transcription of target genes such as p21, Mdm2, Noxa, and Puma, in the absence or presence of DNA damage (Figure 1d, Supplementary Figure S2 ). p53
QSval was deficient in target gene activation and cell cycle arrest at the permissive or restrictive temperature (Supplementary Figure S1B and C), and neither p53
QSala nor p53
QSval induced apoptosis in E1A/ras-transformed MEFs in response to adriamycin or etoposide ( Figure 2a ). In total, the results show that while the val135 mutation does reduce chromatin binding in vivo, the p53 QSala mutant is so deficient in function that the additional val135 mutation does not further compromise its ability to induce p53 target gene expression or to elicit cell cycle arrest or apoptotic functions.
p53 N-terminal transactivation domain is required for tumor suppression in an oncogene-driven xenograft assay
We next determined whether p53
QSval and p53
QSala retained some capacity to suppress tumor formation in
QSval/
QSval
, and QSala cells were sequentially infected with retroviruses encoding E1A-12S and oncogenic Ha-ras (V12), the cells were injected into the flanks of athymic nude mice, and the animals monitored for tumor formation. In contrast to wild-type p53 cells that failed to generate tumors, every mouse injected with p53 QSval -or p53 QSala -expressing cells developed tumors of various sizes, as did mice injected with p53 À/À cells. Average tumor weights were not statistically different in these genotypes (Figure 2b ). Figure 2c shows that most tumors generated by p53
QSval and p53 QSala clones expressed similar levels of the mutant p53 proteins, indicating that expression of these proteins does not prevent tumor growth. Taken together, these data indicate that perturbation of the N-terminal transactivation domain renders p53 inactive with respect to tumor suppression. QSval protein to conformation-specific antibodies. Equal amounts of protein (300 mg) extracted from thymus of p53 À/À , p53
QSval/QSval , and p53 þ / þ mice (untreated or 2 h after 15 Gy girradiation) were immunoprecipitated using conformation-specific antibodies pAb246 (wt conformation) and pAb240 (mutant conformation). pAb421 precipitated total p53 regardless of conformation. The precipitates were fractionated by SDS-PAGE and analysed by Western blotting using the polyclonal antibody CM-5. Only 1/6 of the precipitated protein from p53 QSval/QSval thymus was loaded to compensate for the increased abundance of p53
QSval protein. (b) ChIP assay of p53 responsive promoters in mouse thymus. Mice of the indicated genotypes were either untreated or analysed 2 h after 15 Gy g-irradiation. Polyclonal antibody CM-5 was used to precipitate p53-bound DNA. The amount of p53 response elements bound was quantified by realtime PCR and normalized to input DNA. Error bars represent s.d. from two experiments. (c) ChIP assay of p53 responsive promoters in MEFs expressing indicated alleles. QSala-5 and QSala-6 are two independent clones that express p53
QSala at levels similar to the endogenous p53
QSval (see Supplementary Figure S2 ). Monoclonal antibody pAb421 was used to precipitate p53-bound chromatin from either untreated MEFs or MEFs treated with 0.2 mg/ml adriamycin for 12 h. Binding of the indicated p53 proteins to representative p53-responsive promoters were normalized to the amount of input DNA and compared to the binding of unstressed wild-type p53. Error bars represent s.d. from three independent experiments. Similar results were obtained when polyclonal antibody CM-5 was used for immunoprecipitation. (d) p53-dependent target gene activation after g-irradiation of MEFs expressing indicated alleles. Total RNA was extracted and reverse transcribed using Superscipt III RT (Invitrogen). Transcription of p53 target genes was measured using quantitative PCR and normalized to ARP (acidic ribosomal phosphoprotein P0). The graph shows mRNA levels7s.d. from two independent experiments. Primer sequences are available upon request p53 transactivation and tumor suppression M Nistér et al Spontaneous tumor development occurs with identical kinetics in mice encoding p53
QSval and p53-null alleles
We determined whether p53
QSval suppresses tumor formation by analysing the spectrum and rates of spontaneous tumor development in heterozygous and homozygous mutant mice. We believe this is justified since p53
QSval exhibits significant wild-type conformation in mouse tissues (see above), and we were unable to detect differences in the biological functions of p53 QSval and p53
QSala (Figures 1-2 , Supplementary information, Figure S2 ). p53 þ /QSval mice were intercrossed to obtain
, and p53 QSval/QSval offspring. The results were compared to data obtained from p53 þ /À and p53
mice of the same genetic background (Donehower et al., 1992; Jacks et al., 1994) and bred under similar conditions. Like the p53-null allele, p53 QSval had a mild effect on embryonic development (see Supplementary Information).
p53-null mice developed life-threatening thymic lymphomas and/or sarcomas by 15-30 weeks of age. Survival measurements (Figure 3 ) revealed no statistical differences between mice that were homozygous for the p53
QSval or null alleles (P ¼ 0.47). The median survival time (t 50 ) for both p53
QSval/QSval and p53 À/À mice that developed tumors was approximately 150 days after birth ( Figure 3 and Table 1a ). Tumor penetrance was very high in both genotypes; 67/76 (88%) of the p53 QSval/ QSval and 26/31 (84%) of the p53 À/À mice developed malignancies within the experimental timeframe. The survival data presented here agree well with previous studies (Venkatachalam et al., 1998) . E1A-and Ras-expressing MEFs with the indicated p53 alleles were treated with either 0.2 mg/ml adriamycin or 2.5 mM etoposide, and apoptosis was assessed 24 h following treatment by scoring annexin V-positive cells using flow cytometry. The percentage of cell death induced by the drugs was normalized to that of spontaneous death in corresponding untreated cells. The bar graph represents average cell death7s.d. from at least two independent experiments. (b) Average size of tumors in athymic nude mice generated by oncogene-expressing MEFs with the specified p53 alleles. E1A-and Ras-expressing MEFs were injected into the flanks of athymic nude mice. At 2 weeks after injection, the resulting tumors were isolated and weighed. The bar graph represents average tumor weight7s.d. The total number of injected mice (n) for each cell type in two experiments is noted. (c) Comparison between tumor size and p53 QS protein level. Proteins were extracted from individual tumor samples to assay for p53 protein expression by Western blot (upper panel) and results compared to tumor weight (lower panel). In parallel, p53 protein level was also measured in the E1A-and Ras-expressing cells used for mouse injection QSval and p53-null mice of X75% C57Bl/6 background were analysed, and the wild-type mice obtained from heterozygous crossings were analysed separately for the p53 QS and p53-null mice. In total, 634 mice were analysed, including 76 p53
When the tumor-specific survival of wild-type, heterozygous, and homozygous mice were compared within each mutation group, the differences in survival were all found to be highly significant (p53 QSval/QSval vs p53
and p53 þ /À mice were very similar (P ¼ 0.53), as were p53
QSval/QSval and p53 À/À mice (P ¼ 0.47). The statistical analysis was limited to 15 months, but mice were followed for up to 2 years to allow for a more detailed observation of the heterozygotes p53 transactivation and tumor suppression M Nistér et al
Although p53
QSval and p53-null alleles were experimentally indistinguishable with respect to tumor development, the more stable but defective p53
QSval protein could conceivably compromise the activity of the wild-type protein in heterozygotes by oligomerizing with wild-type p53. However, the survival curves for p53 þ /QSval and p53 þ /À mice were the same, within statistical confidence intervals (P ¼ 0.53), and 50% of p53 þ /QSval mice and p53 þ /À mice died with tumors by approximately 570 days after birth (Figures 3, 4 and Table 1a ) (statistical analyses were limited to 15 months and data were censored to remove noncancer-related mortality). Therefore, there is no statistically significant tumor-related survival difference between animals carrying p53-null or p53
QSval alleles in a homozygous or heterozygous configuration.
p53
QSval and p53-null alleles elicit the same tumor spectra Different tumor spectra in p53 QSval and p53-null mice could occur if the p53
QSval allele retains some function in specific cell types due to tumor suppressor functions unrelated to transactivation. Therefore, we autopsied animals of each genotype to ascertain the frequencies of specific tumor types. Table 1b shows that the tumor incidences were the same in animals with corresponding genotypes, regardless of whether they contained p53 QSval or p53-null alleles. The incidence of lymphoma was 62 and 68%, respectively, in the homozygous p53
QSval and p53-null mice and 12 and 10%, respectively, in the corresponding heterozygous mice. Sarcomas occurred equally often in all four analysed groups and the incidence of this tumor type was higher than the lymphoma incidence in heterozygotes (Table 1b) , as noted in previous studies on p53-null mice (Donehower et al., 1992; Venkatachalam et al., 1998) .
The lymphomas were subgrouped into lymphomas with thymic presentation and lymphomas with general presentation. Thymic lymphomas were more common in the homozygous mice, whereas lymphomas with general presentation showed a somewhat higher incidence in the heterozygous groups of mice (cf. Table 1b ). Sarcomas were also subgrouped. Osteosarcomas were observed only in the heterozygous animals, while angiosarcomas were somewhat more common in the homozygous groups (Table 1b) . Importantly, the incidence and latency of specific tumor types were similar in mice carrying either p53
QSval or p53-null alleles (Figure 4a and b). Figure 5 reveals no systematic differences between p53
QSval and p53-null mice with respect to the histopathology of the tumors within each subclass.
p53 QSval/QSval mice also developed tumors other than lymphomas and sarcomas (Table 1c) . By contrast, we did not observe these 'other' tumor types in homo- 
NE: not evaluable, in groups with p3 mice (Donehower et al., 1992 . Both groups of heterozygous mice developed epithelial tumors, mostly at older age. In summary, in considering all parameters of tumor development, the p53
QSval allele behaves as a null allele.
Tumor LOH analysis indicates that p53
QSval behaves as a null allele
Tumors developing in p53
þ /À animals frequently retain one functional wild-type allele (Venkatachalam et al., 1998 (Venkatachalam et al., , 2001 . Although the data reported above indicate that the stable p53
QSval protein does not act in a dominant negative fashion, it is possible that it might exhibit some residual function relevant to tumor suppression. Were this true, one might expect a higher frequency of wild-type allele loss. We therefore determined the frequency with which the wild-type allele was lost from tumors in p53 þ /À and p53 þ /QSval mice by allelespecific PCR (Table 2 , Supplementary information, Figure S3 ). Five of 18 (28%) tumors from p53 þ /QSval mice and 2/9 (22%) tumors in p53 þ /À mice lost the wildtype allele. This frequency is low compared to previous reports (Venkatachalam et al., 1998) where approximately 50% of the p53 þ /À tumors lost the wild-type allele. This discrepancy could be due to the small number of tumors investigated here and/or to methodological differences. Nonetheless, we found no difference in allele loss whether the mutant allele was null or p53 QSval . We conclude that the p53
QSval allele is equivalent to a null allele with regard to retention of the wild-type allele during spontaneous tumor development in heterozygotes.
Activity of the p53
QSval allele in suppressing tumor progression p53 inactivation is often associated with tumor progression involving activated oncogenes. Furthermore, most tumors in humans develop from compromised cells in a Gonadal tumor (teratocarcinoma) 15.8 Figure 4 Latency of tumor development in homo-and heterozygous mice. Tumor-specific survival curves are shown for all lymphomas (a) and sarcomas (b) in homo-and heterozygotes. The latency of lymphoma development was shorter in homozygotes than in heterozygotes (a). This difference was statistically significant in p53-null mice, while there was a tendency for such a difference in p53 QSval mice (p53 À/À vs p53 þ /À , P ¼ 0.015; p53
QSval/QSval vs p53 þ /QSval , P ¼ 0.09). Notably, the longer latency in heterozygotes was associated with a higher fraction of lymphomas with general presentation (cf. Table 1a and b). Similarly, the latency of sarcoma development was shorter in homozygotes than in heterozygotes (b) even though the overall sarcoma incidence was approximately the same in hetero-and homozygotes. However, the sarcoma subtype spectrum was different in homo-and heterozygotes (cf. QSval retained function as a tumor suppressor in such a context. In epithelial cells of the choroid plexus (CP; in brain), as in most epithelia in the mouse, p53 inactivation does not predispose to tumorigenesis (Donehower et al., 1992; Jacks et al., 1994) . However, inactivation of pRb and related proteins, p107 and p130, by cell-specific expression of T 121 (a truncated SV40 Tantigen fragment) changes the selective milieu. In TgT 121 mice, this normally nondividing epithelium becomes hyperproliferative, resulting in activation of a p53-dependent apoptotic response. In a p53 nullizygous background, apoptosis is reduced by 85% and tumors grow at an accelerated rate, reducing survival time by seven-fold (Symonds et al., 1994) . Thus, this system provides a sensitive quantitative assay for p53 tumor suppressor function in vivo. Furthermore, several p53 target genes, including p21, Bax, Gadd45, and Mdm2, are induced upon p53 activation in CP, providing an in vivo assay for p53 transactivation functions (Yin et al., 1997; Lu et al., 2001; and TVD unpublished) . Thus, to test p53
QSval function in response to proliferative stress in vivo, we generated TgT 121 mice in which one or both p53 alleles harbored the p53
QSval mutations.
Analysis of CP apoptosis indicated that the p53
QSval allele behaves as a null allele with respect to this function. The apoptosis was high in TgT 121 tissue, and it was reduced in TgT 121 p53 QSval/QSval tissue to the same extent as in TgT 121 p53 À/À tissue. Furthermore, this decrease in apoptosis resulted in the same acceleration of tumor growth and reduction in survival time as observed by complete inactivation of p53 (Figure 6 ), thus establishing the link between p53 transcriptional regulation, apoptosis, and tumor suppression.
The TgT 121 tumor model is also useful for the examination of tumor progression under selective pressures elicited by p53-dependent apoptosis. In TgT 121 p53 þ /À mice from birth to about 6 weeks of age, the CP is dysplastic and consists of both proliferating and apoptosing cells. However, at 6-8 weeks, focal solid tumors arise that exhibit decreased apoptosis as well as angiogenesis (Lu et al., 2001) . Tumors grow aggressively causing death by an average of 12 weeks (Figure 6a) , and 90% undergo selective loss of the wild-type p53 allele. In the remaining 10% of tumors, p53 is inactive based on the loss of p53-dependent p21 induction (Pan et al., 1998; Lu et al., 2001) .
In each of these assays, p53 QSval functioned as a null allele. Survival of TgT 121 p53 þ /QSval mice followed the same kinetics as that of TgT 121 p53 þ /À mice (Figure 6a ). Analysis of tumor morphology during progression showed the same development of focally aggressive tumors within the same timeframe ( Figure 7A, f and h ). QSval and p53-null mice. There were no systematic differences between p53
QSval and null mice with regard to the histopathological appearance of tumors for each tumor type. For example, among sarcomas, high and low differentiated fibrosarcomas were found in both groups as were histiocytic (MFH, malignant fibrous histiocytoma-like) tumors. Tumor morphology is exemplified by tumors occurring in p53 þ /À (a, c, e); p53 þ /QSval (b, d, f); p53 À/À (g); and p53
QSval/QSval (h) mice. The diagnoses are osteosarcoma (a, b); fibrosarcoma (low differentiated) (c, d); lymphoma (with general presentation) (e, f); and lymphoma (with thymic presentation) (g, h). Photographs were obtained with a Leica microscope, 20 Â objective, and digital camera Figure 7A , d and f) as in p53-null heterozygotes, indicating that p53 was functioning as expected and was not affected by the presence of abundant p53 QSval protein. Furthermore, tumors arising from dysplastic tissue within the same section were devoid of p21 RNA, indicative of loss of p53 function ( Figure 7A, d and f) .
To determine whether the selective pressure for wildtype p53 inactivation had been affected by the presence of a single p53
QSval allele, terminal tumors were analysed for LOH using semiquantitative allele-specific PCR analysis. Of 13 tumors analysed, 10 showed clear loss of the wild-type p53 allele, while all tumors retained the p53
QSval allele ( Figure 7B ). Thus, the high selective pressure for inactivation of the wild-type p53 allele is unchanged in TgT 121 p53 þ /QSval mice compared to TgT 121 p53 þ /À mice. Furthermore, the complete retention of the p53
QSval allele in progressed tumors confirms that this allele behaves as a null allele. Taken together, in the context of tumor growth and progression initiated by pRb pathway disruption, p53
QSval alleles behave as p53-null alleles with respect to apoptotic response, selective pressure for wild-type p53 allele loss, and the morphological and biological characteristics of tumor progression. QSval/QSval (c, e) and TgT 121 ;p53 þ /QSval (d, f) terminal mice were examined for p21 expression by in situ RNA hybridization (c, d) and for tumor morphology (e, f). The CP-containing region is framed with dotted lines. The p21 transcript is undetectable in TgT 121 ;p53
QSval/QSval (c, e) and in the solid tumor of TgT 121 ;p53
, while it is expressed in adjacent dysplastic CP (d, f). In comparison, H&E stains of TgT 121 tumors with p53 À/À (g) and p53
þ /À (h) genotypes are presented. p21 RNA was previously shown to be absent in p53 À/À and p53 LOH tumors in the same manner as shown here for p53
QSval (Lu et al., 2001) . Note the similarities of tumors in heterozygotes and homozygotes of p53 
Discussion
The studies presented here aimed to determine the role of transcriptional regulation function of p53 in tumor suppression. Mutations in codons 25 and 26 interfere with association of p53 and the basal transcriptional machinery (Lin et al., 1994) , and should thus produce a severely disabled regulatory protein. Indeed, we showed that when expressed at physiological levels, the mutated p53 protein (p53 QSala ) failed to induce a number of target genes. Similar results were obtained in differentiated ES cells harboring an independently generated p53 QS mutant (Chao et al., 2000) . These observations indicate that a second proposed N-terminal transactivation domain (Venot et al., 1999) either does not function at physiologically relevant expression levels, or that it must depend on the N-terminal domain containing residues 25 and 26.
C-terminal acetylation of p53 was initially reported to be required for its binding to p53 response elements (Gu and Roeder, 1997) , but recent studies have challenged this concept (Espinosa and Emerson, 2001) . Our chromatin immunoprecipitation (ChIP) results additionally confirmed that acetylation of p53 is not necessary for its DNA-binding activity as p53 QSala , which is not detectably acetylated (Chao et al., 2000) , binds to native chromatin as strongly as the damage-activated wild-type protein. Moreover, p53 QSala binds DNA in the absence of any stress, implying that stress-induced modifications of p53 do not play an essential role in regulating DNA binding. Therefore, p53 activation must be achieved by other mechanisms such as recruitment of coactivators and modification of chromatin structure (Barlev et al., 2001) or destruction of the negative regulator, MDM2 (Stommel and Wahl, 2004) .
In several systems, the ability of p53 to suppress tumor formation depends on its ability to generate an apoptotic response. Both transcription-dependent andindependent mechanisms have been proposed for p53-induced apoptosis. Recently, a role for p53 in the direct induction of mitochondrial apoptosis, independent of transcriptional regulation has emerged (Dumont et al., 2003; Mihara et al., 2003; Chipuk et al., 2004; Leu et al., 2004) . It is noteworthy that MEFs obtained from the p53 QSval mice we generated did undergo apoptosis when treated with wheat germ agglutinin, which was taken as evidence supporting a cytoplasmic, transcription-independent apoptotic mechanism (Chipuk et al., 2004) . In addition, interaction between the p53 central DNAbinding domain and Bcl-2 family members, Bak or BclXL (Mihara et al., 2003; Leu et al., 2004) , has also been reported to induce transcription-independent apoptosis. However, our data clearly demonstrate that p53
QSval does not induce apoptosis in vitro or in vivo under a variety of conditions, and is completely unable to suppress tumor formation in spontaneous and oncogene-initiated models. Furthermore, consistent with our data concerning p53 QSala , Chao et al. (2000) also observed defective apoptosis in p53 QS thymocytes, indicating that defective apoptosis is most likely a direct consequence of the defective transactivation domain generated by the p53 QS mutations. Taken together, these data strongly suggest that p53 elicits apoptotic function through its transcriptional regulation activity. However, we cannot exclude the possibility that inefficient translocation of either p53
QSval or p53 QSala proteins to the cytoplasm also contributes to reducing the effectiveness of the apoptotic response.
Here, we employed several mouse model systems to measure the tumor suppression function of the p53 QSval mutant. One system examines p53 in suppressing spontaneous tumorigenesis; the other determines the role of p53 in suppressing oncogene-initiated tumor formation. In each system, the p53
QSval allele behaves like a p53-null allele. p53
QSval and p53-null mice exhibit identical tumor kinetics and tumor spectra. In addition, the presence of the abundant p53
QSval protein does not alter the selective pressure for specific loss of the wildtype p53 allele in heterozygous mice. The most direct interpretation of these data is that p53
QSval is inactive with regard to in vivo biological functions in mouse tissues at risk for tumor formation.
Given the severe impact of the QS mutations on transactivation, it is not surprising that p53
QS proteins with or without the val135 mutation exhibit no biological differences. In support of this interpretation, the p53 QS mutation introduced into ES cells independently by Chao et al. (2000) using a different genomic targeting construct showed identical biologic properties as those of p53 QSval . Furthermore, although several reports showed that p53 val135 expressed at high levels in transgenic mice elicited tumor predisposition (Lavigueur et al., 1989; Harvey et al., 1995) , the tumor spectrum differed from that of the p53 QSval mice described in this work. Intriguingly, another group reported no adverse effect when the same mutant was expressed at high levels in several tissues (Lozano and Levine, 1991) . Studies with human p53 showed that the val135 mutation still allows p53 to induce apoptosis in E1A-Ras-transformed MEFs, while the triple mutation L22QW23Sval135 completely prevents apoptosis (Sabbatini et al., 1995) . This supports our interpretation that the QS mutations are so severe with regard to compromising the transcriptional function of p53 that the val135 mutation does not exert additional negative effects. Finally, although the val135 mutation was reported to act in a dominant negative fashion to accelerate tumor development in mice carrying wild-type p53 alleles (Harvey et al., 1995) , we show here that p53
QSval does not act in this manner in vivo, nor does it interfere with wild-type p53 in a skin tumorigenesis assay (Weinberg, Niste´r, Wahl et al., in preparation) .
Taken together, the compelling tumorigenicity and functional data suggest that the severe defect in transcriptional regulation caused by the QS mutations accounts for the loss of tumor suppression in multiple mouse tissues. We did not find any evidence that binding of transcriptionally inactive p53 to its responsive promoters could contribute to tumor suppression. Our data indicate that other proposed transcription-independent functions of p53, such as direct interaction with DNA repair proteins, either are not important for tumor p53 transactivation and tumor suppression M Nistér et al suppression, or must depend on the N-terminal transactivation domain and thus play a role in concert with or downstream of transcriptional regulation. However, our data do not exclude the possibility that additional transcription-independent functions mediated by the central DNA-binding domain may contribute to the efficiency of tumor suppression in some tissues or under specific conditions not examined here. On the other hand, the extremely high incidence of DNA-binding domain mutants in human cancers, combined with our analyses, lead us to propose that the transcriptional regulatory function of p53 is paramount for tumor suppression.
Materials and methods
Mice
p53
QSval mice (Jimenez et al., 2000) were bred to X75% C57Bl/ 6 background before initiation of the tumorigenesis studies described here. The p53-null mice (Donehower et al., 1992) had a similar C57Bl/6 background (close to 100% C57Bl/6) at the time of these studies. p53
þ /QSval mice were intercrossed for several generations as were p53 þ /À mice. Mice were killed when visible tumors appeared or upon symptoms of disease. Most mice were followed for up to 15 months, while a subgroup was followed further to enable tumor detection in heterozygotes.
To generate TgT 121 ;p53 þ /QSval and TgT 121 ;p53 QSval/QSval mice for the analysis of brain tumor formation, p53
QSval/QSval mice were crossed to TgT 121 mice for one or two generations, respectively. Generation, screening, and characterization of TgT 121 (B6D2) mice were described previously (Symonds et al., 1994) . Mice utilized for apoptosis assays were killed at 3-4 weeks prior to tumor progression. Mice for survival analysis were killed when the presence of brain tumors was apparent by cranial bulging.
Mouse genotyping and detection of allele loss in tumors
Allele analysis was carried out by PCR (see Supplementary information).
Analysis of mice
All mice were autopsied. Heart, lungs, thymus, spleen, lymph nodes, liver, brain, and digestive and urogenital organs were macroscopically examined for spontaneous tumor formation. Some mice presented with paralysis of hind legs, in which cases the vertebral column and spinal cord were investigated. Organs with macroscopically visible alterations were sampled, and samples fixed in 4% paraformaldehyde, embedded in paraffin, sectioned and stained with H&E for histopathological evaluation. All sections were evaluated by the same investigator. Tumors were categorized as lymphoma, sarcoma, and 'other' to enable statistical comparison of tumor types between genotypes. Lymphomas were categorized as thymic lymphoma when only localized in thymus and other parts of the thoracic cavity and as 'generalized' when also involving other organs or found only in extrathoracic location(s). Sarcomas were also subclassified where possible. Samples from tumor and normal tissue were frozen in liquid nitrogen and kept at -70 o C for genotype analysis. Brains from mice with TgT 121 genotypes were analysed after fixation and paraffin embedding.
Statistical methods
Survival curves were calculated with the Kaplan-Meier method. Cause-specific survival was used; mice affected by causes other than tumors and mice alive at the end of followup were censored. Differences in survival were analysed with the log rank test. The median survival from different tumors was used as a surrogate marker for tumor latency. Difference in proportions of tumors between groups were analysed with w 2 or Fisher exact test in cases where less than five mice comprised a group. All analyses were performed with the Statistica Software 6.0.
In situ assays
Paraffin-embedded brain sections were analysed for apoptosis using the Apoptag kit (Intergen, NY, USA) and results were quantified as previously described (Symonds et al., 1994; Yin et al., 1997) . In situ RNA hybridization was carried out as previously described (Pan et al., 1998) .
Immunoprecipitation, ChIP, and real-time quantitative PCR
ChIP assay was performed as described (Kaeser and Iggo, 2002) with modifications described in detail in Supplementary Information.
Generation of stable cell lines expressing p53
QSala , cell culture, apoptosis assay, and xenograft assay in athymic nude mice
The open reading frame of p53
QSala was cloned into lentiviral expression vector pLenti6/V5-DEST (Invitrogen) using the Invitrogen Gateway System. A ClaI-BamHI fragment containing the CMV promoter was removed and replaced with a PacI-BamHI fragment containing the mouse ubiquitin C promoter from plasmid c-FUW (provided by D Baltimore) following Klenow fill-in. Lentiviruses were prepared from the resulting construct, pLentiQS-Ubc, and used to infect early passage p53 À/À MEF cells following the manufacturer's protocol. Stable clones expressing p53
QSval were picked and expanded after selection in 3 mg/ml blasticidin. MEFs were maintained in DMEM plus 15% FBS, 100 mM b-mercaptoethanol, 2 mM Lglutamine, antibiotics, and for p53 QSala clones 3 mg/ml blasticidin.
Preparation of retroviruses expressing E1A-12S or Ha-ras, retrovirus infection, and xenograft assays in athymic nude mice were as described Jimenez et al. (2000) . E1A-and Ras-expressing MEFs were treated with 0.2 mg/ml adriamycin or 2.5 mM etoposide to induce apoptosis. After 24h, floating and adherent cells were collected and stained with annexin V-FITC. Apoptosis was scored by flow cytometry.
Note Added in Proof
We recently obtained new stable cell lines expressing p53 QSala , and found that several grew more slowly than either p53 QSval MEFs, or p53
QSala subclone 5 used in the studies in this paper. The p53
QSala expression in the new clones was high, and heterogeneous, suggesting that compromised growth may result from very high expression of p53 QSala . It is possible that p53
QSala does retain some transcriptional activity manifested when it is expressed at high levels, or that excessive levels of a transcriptionally inactive protein that binds stably to numerous promoters and cannot be removed by proteolysis can adversely affect cell growth. 
